Last updated 3 days ago
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
1440 patients around the world
Available in Guatemala, Argentina, United States
Merck Sharp & Dohme LLC
8Research sites
1440Patients around the world
This study is for people with
Prostate cancer
Metastatic prostate cancer
Castration resistant prostate cancer
Requirements for the patient
From 18 Years
Male
Medical requirements
- Has diagnosis of metastatic castration-resistant prostate cancer (mCRPC).Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months prior to entering the study.Has received prior treatment with 1 or 2 androgen receptor pathway inhibitor (ARPI) and progressed during or after at least 8 weeks of treatment.
- History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids.Has uncontrolled or significant cardiovascular disease.Has received prior treatment with a taxane-based chemotherapy agent for mCRPC.
Sites
Instituto San Marcos Investigación - San Juan
Recruiting
Instituto de Investigaciones Clínicas Mar del Plata
Recruiting
Fundación Cori para la Investigación y Prevención del Cáncer - La Rioja
Recruiting
Centro Oncológico de Integración Regional C.O.I.R.
Recruiting
Fundación Respirar
Recruiting
Centro de Diagnóstico Investigación y Tratamiento - CEDIT - Salta
Recruiting
Sanatorio Parque - Rosario
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
StudyIDeate-Prostate01
SponsorMerck Sharp & Dohme LLC
Study typeInterventional
Conditions
Metastatic prostate cancerCastration resistant prostate cancer
Requirements
From 18 YearsMale
Unique study IDclinicaltrials.gov
NCT06925737
